Specifically, inhibition of the programmed cell death protein (PD1) and its ligand (PD-L1) with the agents, nivolumab and pembrolizumab, has resulted in improved survival in cancers including melanoma and non-small cell lung adenocarcinoma [41,42]. Here, CD274 is linked to melanoma.